DeutschNewstral
Article
jdsupra.com on 2017-12-22 20:03
FDA Issues Draft Guidance on Orphan Drug Designation in Pediatric Subpopulations
Related news
SA biotech gets FDA orphan drug designationbizjournals.com- FDA Issues Draft Guidance for Obtaining Qualified Infectious Disease Product Designation Under the GAIN Actjdsupra.com
- FDA Issues Draft Guidance on Its New Platform Technology Designation Programjdsupra.com
Sapience Therapeutics ST-36 receives orphan drug designation from FDAwestfaironline.com- MProQR shares rises on FDA orphan drug designationmarketwatch.com
- FDA grants rare pediatric disease designation to RegenxBio gene therapybizjournals.com
- Break On Through to the Other Side, Part 2: FDA Issues Draft Guidance About Breakthrough Therapy Designation Rescissionjdsupra.com
- FDA finalizes guidance on Orphan Drug “sameness” of gene therapiesjdsupra.com
- FDA Issues Draft Guidance on Biosimilar Interchangeabilityjdsupra.com
- FDA Issues Draft Guidance on Remanufacturingjdsupra.com
- FDA Issues New Draft Guidance on Allergensjdsupra.com
- FDA Announces New Draft REMS Guidancejdsupra.com
- FDA Draft Guidance on Menu Labelingjdsupra.com
- FDA Releases Medical Device Cybersecurity Draft Guidancejdsupra.com
- Orphan Drug Designationjdsupra.com
- MSeres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapymarketwatch.com
- Imbrium Therapeutics receives FDA orphan drug designation for biliary tract cancer drugwestfaironline.com
- MAkari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopanmarketwatch.com
- MOrgenesis shares soar 19% premarket after FDA grants orphan designation to insulin techmarketwatch.com